Summary
Becton, Dickinson and Company (BDX) has filed an 8-K report on October 15, 2025, primarily to announce preliminary unaudited revenue figures for its fourth quarter and full fiscal year ended September 30, 2025. While specific revenue numbers are not detailed in the 8-K text itself, investors are directed to Exhibit 99.1, a press release, for these details and a discussion of non-GAAP financial measures. This filing also discloses a significant leadership change: Executive Vice President and Chief Financial Officer, Christopher J. DelOrefice, will resign effective December 5, 2025, to pursue a new opportunity. His departure is stated to be amicable and not due to any disagreements regarding financial matters. Vitor Roque, currently Senior Vice President of Finance, Business Units and Corporate Financial Planning & Analysis, has been appointed interim Chief Financial Officer, effective upon Mr. DelOrefice's departure. Mr. Roque brings extensive experience within BDX, having held various senior finance roles, including CFO of the BD Medical Segment. The company is actively searching for a permanent CFO. Investors should review the furnished press release for detailed preliminary financial results and consider the implications of the CFO transition on future financial reporting and strategy.
Key Highlights
- 1BDX announced preliminary unaudited revenue for Q4 and full fiscal year 2025 in a press release furnished with this 8-K.
- 2Investors are directed to Exhibit 99.1 (press release) for detailed financial results and non-GAAP measures.
- 3EVP and CFO Christopher J. DelOrefice is resigning effective December 5, 2025.
- 4Mr. DelOrefice's departure is not due to any disagreements concerning financial statements, internal controls, or operations.
- 5Vitor Roque, SVP of Finance, has been appointed interim Chief Financial Officer.
- 6Mr. Roque has significant finance leadership experience within BDX, including as CFO of the Medical Segment.
- 7BDX is conducting a search for a permanent Chief Financial Officer.